The Clarivate Analytics announced the impact factor of the Cellular & Molecular Immunology (CMI) to be 7.551 for 2017 on June 27. CMI now ranks in Q1 category (top 25%) and 16 of 155 (10th with the review journals excluded) among the international immunology journals, rising from 26th in 2016. Besides, CMI is currently the 8th out of 203 Chinese SCI journal and the 1st academy-run journal worldwide (US, Europe and Japan).

CMI ranks as the 16/155 immunology journal internationally (top) and receives record high impact factor of 7.551 for 2017 (bottom) / Images from USTC News Center

Led by Editors-in-Chief Academicians CAO Xuetao and TIAN Zhigang, CMI is the monthly Nature Publishing Group journal from the Chinese Society for Immunology (CSI) and USTC. CMI has been abstracted by the top-tier indexes such as the Science Citation Index (SCI), the Chemical Abstracts Service (CAS), the Journal Citation Reports, the MEDLINE/PubMed, the SCImago, the Chinese Journal Full-text Database (CJFD) and the Chinese Science Citation Database (CSCD). In addition to the wide-range indexes, CMI has won a number of prestigious awards such as the Outstanding International Journal awards from the China Association for Science and Technology (CAST) during 2016 to 2018, the Top Academic Journal award from the Chinese Academy of Sciences (CAS) in 2018 and the Highest International Impact Academic Journals of China awards co-issued by the China Academic Journals e-Publishing Co. Ltd. and the Tsinghua University Library during 2012 to 2017.

As the China’s only English-language immunology journal, CMI serves both the Chinese and the international communities from 56 counties/regions as a vehicle to rapidly disseminate the latest studies in the fields of both basic immunology research and clinical applications.

(Written by XU Yunfei, edited by YANG Xinqi, USTC News Center)